Several in vitro studies have suggested that, if anti-VEGF therapy fails, anti-VEGF therapy may cause more severe hypoxia in the tumor microenvironment, leading to tumor progression and greater malignancy or inducing metastasis22–25. The gene discussed is VEGFA; the disease is neoplasm.